SCHEMBL1503106

SCHEMBL1503106

COc1ccc(COCc2cnc(C(=O)NOCc3ccccc3)c3c2COC(C)(C)O3)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
ALDH1A1 P00352 5/20 0.36
KDM4E B2RXH2 1/20 0.36
VNN1 O95497 1/20 0.35
AURKA O14965 1/20 0.35
CCNA2 P20248 1/20 0.35
CDK2 P24941 1/20 0.35
CCNA1 P78396 1/20 0.35
KMT2A Q03164 2/20 0.35
MAPK1 P28482 1/20 0.35
GSK3B P49841 1/20 0.35
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
CYP1A2 P05177 2/20 0.34
CYP3A4 P08684 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
EGLN1 Q9GZT9 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1503084 0.88 SMPD1 (0.39) ALDH1A1CCNA2CDK2CCNA1KMT2A
SCHEMBL1503087 0.87 EGLN1 (0.40) NPC1RAB9AALDH1A1KDM4ECCNA2
SCHEMBL30193010 0.86 ALDH1A1 (0.39) NPC1RAB9AALDH1A1KDM4EVNN1
SCHEMBL1503248 0.86 ALDH1A1 (0.39) NPC1RAB9AALDH1A1KDM4EVNN1
SCHEMBL2220510 0.82 UCHL1 (0.40) ALDH1A1CCNA2CDK2CCNA1KMT2A
SCHEMBL12444362 0.80 ALDH1A1 (0.40) NPC1RAB9AALDH1A1KDM4EKMT2A
SCHEMBL1503186 0.79 MAPK1 (0.41) ALDH1A1KDM4EKMT2AMAPK1MAPT
SCHEMBL1503272 0.78 NPC1 (0.52) NPC1RAB9AALDH1A1KDM4EVNN1
SCHEMBL2219213 0.78 ALDH1A1 (0.57) ALDH1A1KDM4EKMT2AMAPK1MAPT
SCHEMBL1503282 0.77 ALDH1A1 (0.40) NPC1RAB9AALDH1A1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8742123-B2 HIV integrase inhibitors from pyridoxine TAIMED BIOLOGICS, INC. (TW) 2014-06-03 US claimed
US-8742123-B2 HIV integrase inhibitors from pyridoxine TAIMED BIOLOGICS, INC. (TW) 2014-06-03 US disclosed
US-20110178120-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE AMBRILIA BIOPHARMA, INC. (CA) 2011-07-21 US disclosed
EP-2300433-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE Ambrilia Biopharma Inc. (CA) 2011-03-30 EP disclosed
WO-2009146555-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE AMBRILIA BIOPHARMA INC. (CA) 2009-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178120-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE PNPO, CCNB1, BLVRB NPC1 3046/4885RAB9A 3692/4885ALDH1A1 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.